White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
Diagnosis
Table 1. Patient Risk Factors for...
...ent Risk Factors for Poor Clinical Outcomes Result...
Treatment for Adult Patients
...for Adult Patients...
Primary prophylaxis with a CSF starting wi...
...ry prophylaxis with a CSF is recommended for...
CSFs should not be routinely used for pa...
...be routinely used as adjunctive trea...
...breast cancer and lymphoma] ( EB , H ,...
...urothelial cancer] ( EB , H , H , M...
CSFs may be used alone, after chemot...
...uld be administered after autologous st...
...be administered after allogeneic stem-cell...
...Fs for patients with diffuse aggressive lym...
...lgrastim, filgrastim, tbo-filgrastim, and filgras...
...commendations for the management of...
Treatment for Pediatric Patients
...reatment for Pediatric Patients
...e use of CSFs in pediatric patients wi...
...atric indications in which dose-intense chemother...
...not be used in pediatric patients with nonrelapse...
Table 3. Dosing and Administration of CSFs
...3. Dosing and Administration of CSFsHavin...